Resistant hypertension: What the cardiologist needs to know

European Heart Journal

Volumn 36, Issue 40, 2015, Pages 2686-2695c

  Rimoldi, Stefano F ^a   Messerli, Franz H ^a,b   Bangalore, Sripal ^b   Scherrer, Urs ^a,c  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c UNIVERSIDAD DE TARAPACÁ   (Chile)

Author keywords

Arterial hypertension; Arterial stiffness; Isolated systolic hypertension; Renal denervation; Secondary hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT; ANTIHYPERTENSIVE AGENT;

ALCOHOL CONSUMPTION; ARTERIAL PRESSURE; ARTERIAL STIFFNESS; ARTERIOSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CAROTID BARORECEPTOR; CAROTID SINUS PRESSORECEPTOR; CATHETER BASED RENAL DENERVATION; CLINICAL EVALUATION; COMORBIDITY; DRUG EFFICACY; ECHOCARDIOGRAPHY; ELECTROSTIMULATION; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY FUNCTION; MEDICATION COMPLIANCE; MICROALBUMINURIA; MINIMALLY INVASIVE PROCEDURE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PHYSICIAN ATTITUDE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENOVASCULAR DISEASE; RESISTANT HYPERTENSION; REVIEW; SEDENTARY LIFESTYLE; SLEEP DISORDERED BREATHING; SODIUM INTAKE; SYMPATHETIC TONE; SYSTOLIC HYPERTENSION; TARGET ORGAN; TREATMENT CONTRAINDICATION; VASCULAR REMODELING; WATER RETENTION; WHITE COAT HYPERTENSION; BLOOD PRESSURE MONITORING; CARDIOLOGY; CATHETER ABLATION; CHRONIC DISEASE; DEVICES; DRUG RESISTANCE; ELECTROTHERAPY; KIDNEY FUNCTION TEST; PHYSIOLOGY; PROCEDURES; PROSTHESES AND ORTHOSES; SYMPATHECTOMY; TREATMENT FAILURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOLOGY; CATHETER ABLATION; CHRONIC DISEASE; DRUG RESISTANCE; ECHOCARDIOGRAPHY; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; KIDNEY FUNCTION TESTS; PROSTHESES AND IMPLANTS; SYMPATHECTOMY; TREATMENT FAILURE; VASCULAR REMODELING; VASCULAR STIFFNESS;

EID: 84948687935     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv392     Document Type: Review

References (110)

1. Bangalore S, Fayyad R, Laskey R, Demicco DA, Deedwania P, Kostis JB, Messerli FH, Treating to New Targets Steering Committee and Investigators. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med 2014;127:71-81.
2. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O'Connor PJ, Selby JV, Ho PM. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635-1642.
3. Egan BM, Zhao Y, Axon RN, BrzezinskiWA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124:1046-1058.
4. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M, for the ALLHAT Collaborative Research Group. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014;64:1012-1021.
5. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011;57:1076-1080.
6. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:510-526.
7. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Burnier M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Ferrari R, Hasdai D, Hoes AW, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Gillebert TC, Rosei EA, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, Struijker-Boudier H, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-2219.
8. Acharya T, Tringali S, Singh M, Huang J. Resistant hypertension and associated comorbidities in a veterans affairs population. J Clin Hypertens (Greenwich) 2014;16:741-745.
9. Lotufo PA, Pereira AC, Vasconcellos PS, Santos IS, Mill JG, Bensenor IM. Resistant hypertension: risk factors, subclinical atherosclerosis, and comorbidities among adults-the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Clin Hypertens (Greenwich) 2015;17:74-80.
10. Messerli FH, Bangalore S. Treatment-resistant hypertension: another Cinderella story. Eur Heart J 2013;34:1175-1177.
11. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 2010;376:1903-1909.
12. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281.
13. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, for the SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393-1401.
14. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Vehier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G, the Renal Denervation for Hypertension (DENERHTN) Investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015;385:1957-1965.
15. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011;57:898-902.
16. Hayek SS, Abdou MH, Demoss BD, Legaspi JM, Veledar E, Deka A, Krishnan SK, Wilmot KA, Patel AD, Kumar VR, Devireddy CM. Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients. Am J Hypertens 2013;26:1452-1458.
17. Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E. Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension 2014;64:501-507.
18. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005;111:697-716.
19. Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B. Resistant hypertension. BMJ 2012;345:e7473.
20. Fagard RH. Resistant hypertension. Heart 2012;98:254-261.
21. Persu A, O'Brien E, Verdecchia P. Use of ambulatory blood pressure measurement in the definition of resistant hypertension: a review of the evidence. Hypertens Res 2014;37:967-972.
22. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014;35:1245-1254.
23. Kalra PA, Guo H, Kausz AT, Gilbertson DT, Liu J, Chen SC, Ishani A, Collins AJ, Foley RN. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int 2005;68:293-301.
24. Rimoldi SF, de Marchi SF, Windecker S, Meier B, Allemann Y. Screening renal artery angiography in hypertensive patients undergoing coronary angiography and 6-month follow-up after ad hoc percutaneous revascularization. J Hypertens 2010;28:842-847.
25. Messerli FH, Bangalore S, Makani H, Rimoldi SF, Allemann Y, White CJ, Textor S, Sleight P. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome. Eur Heart J 2011;32:2231-2235.
26. Rimoldi SF, Yuzefpolskaya M, Allemann Y, Messerli F. Flash pulmonary edema. Prog Cardiovasc Dis 2009;52:249-259.
27. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-2605.
28. Boutouyrie P, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Massy ZA, Suleymanlar G, Sicari R, Gargani L, Parati G, Mallamaci F, Zoccali C, London GM. Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrol Dial Transplant 2014;29:232-239.
29. Mattace-Raso F, Hofman A, Verwoert GC, Wittemana JC, Wilkinson I, Cockcroft J, McEniery C, Yasmin, Laurent S, Boutouyrie P, Bozec E, Hansen TW, Torp-Pedersen C, Ibsen H, Jeppesen J, Vermeersch SJ, Rietzschel E, De Buyzere M, Gillebert TC, Van Bortel L, Segers P, Vlachopoulos C, Aznaouridis C, Stefanadis C, Benetos A, Labat C, Lacolley P, Stehouwer C, Nijpels G, Dekker JM, Stehouwer C, Ferreira I, Twisk JW, Czernichow S, Galan P, Hercberg S, Pannier B, Guérin A, London G, Cruickshank JK, Anderson SG, Paini A, Agabiti Rosei E, Muiesan ML, Salvetti M, Filipovsky J, Seidlerova J, Dolejsova M. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010;31:2338-2350.
30. Muxfeldt ES, Salles GF. Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension? J Hypertens 2008;26:878-884.
31. Ott C, Schmid A, Toennes SW, Ditting T, Veelken R, Uder M, Schmieder RE. Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. EuroIntervention 2015;11:110-116.
32. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005;18:619-626.
33. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013;31:766-774.
34. Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001;19:335-341.
35. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013;62:218-225.
36. Frisoli TM, Schmieder RE, Grodzicki T, Messerli FH. Beyond salt: lifestyle modifications and blood pressure. Eur Heart J 2011;32:3081-3087.
37. Jordan J, Yumuk V, Schlaich M, Nilsson PM, Zahorska-Markiewicz B, Grassi G, Schmieder RE, Engeli S, Finer N. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens 2012;30:1047-1055.
38. Strazzullo P, Barba G, Cappuccio FP, Siani A, Trevisan M, Farinaro E, Pagano E, Barbato A, Iacone R, Galletti F. Altered renal sodium handling in men with abdominal adiposity: a link to hypertension. J Hypertens 2001;19:2157-2164.
39. Grassi G, Facchini A, Trevano FQ, Dell'Oro R, Arenare F, Tana F, Bolla G, Monzani A, Robuschi M, Mancia G. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005;46:321-325.
40. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003;42:878-884.
41. Hyman DJ, Pavlik VN, Taylor WC, Goodrick GK, Moye L. Simultaneous vs. sequential counseling for multiple behavior change. Arch Intern Med 2007;167:1152-1158.
42. He FJ, Burnier M, Macgregor GA. Nutrition in cardiovascular disease: salt in hypertension and heart failure. Eur Heart J 2011;32:3073-3080.
43. Pimenta E, Calhoun DA. Aldosterone and metabolic dysfunction: an unresolved issue. Hypertension 2009;53:585-586.
44. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009;54:475-481.
45. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutierrez OM, Irvin MR, Lackland DT, Oparil S, Warnock D, Muntner P. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 2013;8:1583-1590.
46. Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG, Conlin PR, Svetkey LP, Erlinger TP, Moore TJ, Karanja N. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med 2001;135:1019-1028.
47. Hallock P, Benson IC. Studies on the elastic properties of human isolated aorta. J Clin Invest 1937;16:595-602.
48. Randin D, Vollenweider P, Tappy L, Jequier E, Nicod P, Scherrer U. Suppression of alcohol-induced hypertension by dexamethasone. N Engl J Med 1995;332:1733-1737.
49. Rosito GA, Fuchs FD, Duncan BB. Dose-dependent biphasic effect of ethanol on 24-h blood pressure in normotensive subjects. Am J Hypertens 1999;12:236-240.
50. Aguilera MT, de la Sierra A, Coca A, Estruch R, Fernandez-Sola J, Urbano-Marquez A. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension 1999;33:653-657.
51. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012;125:14-22.
52. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012;33:1058-1066.
53. Grassi G, Seravalle G, Brambilla G, Pini C, Alimento M, Facchetti R, Spaziani D, Cuspidi C, Mancia G. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. Int J Cardiol 2014;177:1020-1025.
54. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988;11:3-20.
55. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension: results in 1, 266 cases. J Am Med Assoc 1953;152:1501-1504.
56. Ewen S, Ukena C, Linz D, Kindermann I, Cremers B, Laufs U, Wagenpfeil S, Schmieder RE, Bohm M, Mahfoud F. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension 2015;65:193-199.
57. Grassi G, Seravalle G, Brambilla G, Trabattoni D, Cuspidi C, Corso R, Pieruzzi F, Genovesi S, Stella A, Facchetti R, Spaziani D, Bartorelli A, Mancia G. Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects. Hypertension 2015;65:1209-1216.
58. Franklin SS, Gustin WIV, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997;96:308-315.
59. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet 2008;371:2219-2221.
60. von Arx R, Rexhaj E, Allemann Y, Moschovitis A, Windecker S, Meier B, Scherrer U, Rimoldi SF. Lack of blood pressure-lowering effect of renal denervation in a drug-naive patient with pronounced arterial stiffening. Am J Med 2014;127:e3-e4.
61. Krum H, Schlaich M, Sobotka P, Scheffers I, Kroon AA, de Leeuw PW. Novel procedure- and device-based strategies in the management of systemic hypertension. Eur Heart J 2011;32:537-544.
62. Lohmeier TE, Iliescu R. The baroreflex as a long-term controller of arterial pressure. Physiology (Bethesda) 2015;30:148-158.
63. Lohmeier TE, Iliescu R, Dwyer TM, Irwin ED, Cates AW, Rossing MA. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol 2010;299:H402-H409.
64. Wustmann K, Kucera JP, Scheffers I, Mohaupt M, Kroon AA, de Leeuw PW, Schmidli J, Allemann Y, Delacretaz E. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009;54:530-536.
65. Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 2012;59:331-338.
66. Lohmeier TE, Liu B, Hildebrandt DA, Cates AW, Georgakopoulos D, Irwin ED. Global- and renal-specific sympathoinhibition in aldosterone hypertension. Hypertension 2015;65:1223-1230.
67. Lohmeier TE, Dwyer TM, Hildebrandt DA, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension 2005;46:1194-1200.
68. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010;55:619-626.
69. de Leeuw PW, Alnima T, Lovett E, Sica D, Bisognano J, Haller H, Kroon AA. Bilateral or unilateral stimulation for baroreflex activation therapy. Hypertension 2015;65:187-192.
70. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015;21;36:219-227.
71. Mahfoud F, Luscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, Doevendans P, Fagard R, Fajadet J, Komajda M, Lefevre T, Lotan C, Sievert H, Volpe M, Widimsky P, Wijns W, Williams B, Windecker S, Witkowski A, Zeller T, Bohm M. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013;34:2149-2157.
72. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Bohm M, Campese VM, Francis DP, Grassi G, Hering D, Katholi R, Kjeldsen S, Krum H, Mahfoud F, Mancia G, Messerli FH, Narkiewicz K, Parati G, Rocha-Singh KJ, Ruilope LM, Rump LC, Sica DA, Sobotka PA, Tsioufis C, Vonend O, Weber MA, Williams B, Zeller T, Esler MD. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol 2013;62:2031-2045.
73. Rimoldi SF, Scheidegger N, Scherrer U, Farese S, Rexhaj E, Moschovitis A, Windecker S, Meier B, Allemann Y. Anatomical eligibility of the renal vasculature for catheter-based renal denervation in hypertensive patients. JACC Cardiovasc Interv 2014;7:187-192.
74. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R, Joner M. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol 2014;64:635-643.
75. Id D, Kaltenbach B, Bertog SC, Hornung M, Hofmann I, Vaskelyte L, Sievert H. Does the presence of accessory renal arteries affect the efficacy of renal denervation? JACC Cardiovasc Interv 2013;6:1085-1091.
76. Messerli FH, Bangalore S, Schmieder RE. Wilder's principle: pre-treatment value determines post-treatment response. Eur Heart J 2015;36:576-579.
77. Epstein M, de Marchena E. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the 'End of the road' for renal denervation? J Am Soc Hypertens 2015;9:140-149.
78. Mahfoud F, Bohm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE, Luscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L, Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, Witkowski A, WijnsW, Zeller T, Schmieder RE. Proceedings from the European Clinical Consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 2015; doi: 10.1093/eurheartj/ehv192.
79. Mahfoud F, Edelman ER, Bohm M. Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol 2014;64:644-646.
80. Tzafriri AR, Mahfoud F, Keating JH, Markham PM, Spognardi A, Wong G, Fuimaono K, Bohm M, Edelman ER. Innervation patterns may limit response to endovascular renal denervation. J Am Coll Cardiol 2014;64:1079-1087.
81. Mahfoud F, Luscher TF. Renal denervation: simply trapped by complexity? Eur Heart J 2015;36:199-202.
82. Hering D. Renal denervation superior to drug therapy in hypertension. Lancet 2015;385:1922-1924.
83. Wang H, Wang J, Guo C, Luo W, Kleiman K, Eitzman DT. Renal denervation attenuates progression of atherosclerosis in apolipoprotein E-deficient mice independent of blood pressure lowering. Hypertension 2015;65:758-765.
84. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-520.
85. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 2014;16:14-26.
86. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J 2011;32:2499-2506.
87. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004;22:2217-2226.
88. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, Laurent S, Menard J, Plouin PF. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012;30:1656-1664.
89. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
90. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428.
91. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764.
92. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898.
93. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
94. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840.
95. Rimoldi SF, Messerli FH, Chavez P, Stefanini GG, Scherrer U. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens (Greenwich) 2015;17:193-199.
96. Chalmers J, Arima H, Woodward M, Mancia G, Poulter N, Hirakawa Y, Zoungas S, Patel A, Williams B, Harrap S. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension 2014;63:259-264.
97. Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents-a preliminary report. Hypertension 2007;49:272-275.
98. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixeddose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407.
99. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-845.
100. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, Vaclavik T, Husar R, Kocianova E, Taborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011;57:1069-1075.
101. Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008;118:42-48.
102. Chapman N, Chen CY, Fujita T, Hobbs FD, Kim SJ, Staessen JA, Tanomsup S, Wang JG, Williams B. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? J Hypertens 2010;28:1796-1803.
103. Komai N, Ohishi M, Moriguchi A, Yanagitani Y, Jinno T, Matsumoto K, Katsuya T, Rakugi H, Higaki J, Ogihara T. Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation. Hypertens Res 2002;25:5-10.
104. Mann SJ. Drug therapy for resistant hypertension: simplifying the approach. J Clin Hypertens (Greenwich) 2011;13:120-130.
105. Duprez DA. Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J Clin Hypertens (Greenwich) 2007;9:13-18.
106. Muiesan ML, Salvetti M, Rizzoni D, Paini A, Agabiti-Rosei C, Aggiusti C, Agabiti Rosei E. Resistant hypertension and target organ damage. Hypertens Res 2013;36:485-491.
107. Biaggi P, Matthews F, Braun J, Rousson V, Kaufmann PA, Jenni R. Gender, age, and body surface area are the major determinants of ascending aorta dimensions in subjects with apparently normal echocardiograms. J Am Soc Echocardiogr 2009;22:720-725.
108. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.
109. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013;34:1204-1214.
110. Safar ME, Blacher J, Jankowski P. Arterial stiffness, pulse pressure, and cardiovascular disease-is it possible to break the vicious circle? Atherosclerosis 2011;218:263-271.